BBO-10203

2971769-60-3

C18319-1mg

PI3K

PI3K/Akt/mTOR

CN (N=C1) C (C=C2) =C1C=C2C3=NC (C4=NN5C ([C@@H] (C) N (C (C=C) =O) CC5) =C4) =[C@] ([C@]6=C (F) C=C (F) C=C6OCCOC) C7=C3C=CS7

C34H30F2N6O3S

BBO-10203 inhibits PI3Kα and KRASG12C by covalently binding to Cys242 in the PI3Kα RAS-Binding Domain. It inhibits both GTP-bound and GDP-bound KRASG12C states, with IC50 and EC50 values of 0.031 nM and 0.02 nM respectively. This compound interferes with RAS-PI3Kα interaction, suppressing RAS-dependent PI3Kα activation. It decreases pERK levels, inhibits cell proliferation, and causes G1 phase arrest and apoptosis. BBO-10203 has potential applications in breast cancer, colorectal cancer, and non-small cell lung cancer research.

3 years-20°C powder 2 years-80°C in solvent